Introduction
Multiple sclerosis (MS) is a heterogeneous condition which at the extremes can have an extremely benign course, where patients remain independently mobile for many years, or it can have a fulminant course with rapid decline in function in the weeks following diagnosis. Certain clinical factors have a higher likelihood of a more benign course e.g. initial symptom being sensory or visual, younger age at onset, female sex, [1] and a long interval between the first two relapses [2] . However, in an individual patient, it is not possible to accurately predict the course of their illness at the time of diagnosis.
Several genes have been implicated in modifying the course or severity of MS. HLA-DR2 has been shown to favor the progression to MS in patients with clinically isolated syndromes [3] and is associated with earlier disease onset [4] and a relapsing remitting rather than progressive course [5] . The presence of apolipoprotein E-ε4 allele is thought to be an unfavorable prognostic factor [6, 7] , whereas the є2 allele has demonstrated a more favorable effect [8] . Polymorphisms in interleukin (IL)-1ra allele-2 have been found to favorably influence disease outcome in four studies [5, [9] [10] [11] , however, a further two studies did not see such an effect [12, 13] . Polymorphisms in IL-1ra allele-3 have been found to be favorable in a single study [12] . To date, no association has been found between tumor necrosis factor (TNF)-α polymorphisms and disease course or severity [14] [15] [16] [17] [18] .
The Northern Ireland arm of the Genetic Analysis of Multiple Sclerosis in Europeans (GAMES) study and follow-up refined analysis identified 15 microsatellite markers which may locate susceptibility genes for MS in the Northern Ireland population [19, 20] . The present study considered the 12 most significant of these markers in benign onset, aggressive, and primary progressive sub-groups. The aim of this study was to identify any susceptibility genes present in one of the cohorts and not in the others; therefore, it would be a possible marker for that disease outcome. Clinically, primary progressive patients present and behave in a way dissimilar from relapsing remitting patients, of whom 70% progress. Therefore, the most useful test in the clinical setting would be one that could predict a benign or aggressive course in relapsing remitting disease.
Methods

Case ascertainment and classification
Cases were interviewed and examined to confirm the diagnosis. Kurtzke Expanded Disability Status Scale (EDSS) [21] was calculated at attendance and retrospectively at 10 years from onset of first symptom. Individuals recruited gave written consent for genetic analysis. Only cases with benign, aggressive, or primary progressive MS were included in this study. Benign-onset MS was defined as a Kurtzke EDSS ≤ 3.0 at 10 years. Aggressive MS included all cases with Kurtzke EDSS ≥ 6.0 by 10 years. Primary progressive MS was defined as a progressive clinical history from onset of first symptoms, with no clear evidence of relapses or remissions. All cases were Caucasian of Northern Irish origin. The clinical characteristics of each group are documented in Table 1 .
Diagnostic criteria
Those satisfying the Poser criteria for definite or probable MS [22] or the McDonald criteria for MS [23] were included. Clinically isolated syndromes were not included in this study.
DNA extraction
DNA was extracted from venous blood by standard methods. The DNA concentration of each sample was determined by spectrophotometry. Sample concentrations were adjusted to 50 ng/μl.
Polymerase chain reaction
The 12 microsatellite markers tested are detailed in Table 2 . The polymerase chain reaction (PCR) was performed on 10 mcgl reaction volumes using a thermophilic DNA polymerase. The cycle reaction was performed on an Applied Biosystems (Forster City, CA, USA) 9700 thermal cycler according a standard protocol.
Capillary electrophoresis
The products from each PCR were electrophoresed on an Applied Biosystems 3100 Genetic Analyser. Resultant electropherograms were analyzed using GENESCAN (version 3.5) and GENOTYPER (version 3.7) software.
Statistical analysis
The sample size target of 200 per group was justified in the basis of comparing each allele against all the Alleles were typed by fluorescent fragment analysis. Peak height was quantified to identify the major allele. Allele frequencies were initially compared between the three patient subgroups using a chisquared test for 3 x k tables (which was considered valid because all expected values were ≥2.0). In these initial analyses, P values were deemed significant at the level P < 0.0042 (0.05 of 12). Markers showing significant difference were compared for differences between benign and aggressive, benign and primary progressive, and aggressive and primary progressive disease by CLUMP analysis [24] using the T1-statistic with a P value obtained using 10,000 permutations. In these comparisons, a P value of <0.0014 (0.05 of 12 × 3) was deemed significant. Finally, the CLUMP T3-statistic was used to identify which alleles were overrepresented in one group relative to another. This statistic compares each allele with all other alleles combined whilst taking into account the number of alleles at the locus. P values were obtained using 100,000 permutations and a P value of <0.0014 was taken as significant.
Results
A total of 484 patients with MS were recruited in this study as follows: benign onset-181 cases; aggressive-167 cases; and primary progressive-136 cases. The patient characteristics of each group are documented in Table 1 . As expected, the benign onset and aggressive groups were of a younger age, had a significantly higher female to male ratio, and were younger at onset of first symptom than the primary progressive group. The mean Kurtzke EDSS at 10 years were 1.8 for benign-onset cases (range 0.0-3.0), 6.3 for the aggressive cases (range 6.0-7.5), and 5.6 for the primary progressive group (range 2.0-7.5). Table 2 shows that five of 12 microsatellite markers were significant in the initial screening using the 3 x k chi-squared tests with the significance level set at the P < 0.0042 level: D3S1278 (Chr 3q13, P < 0.001), D4S432 (Chr 4p16, P = 0.001), D2S347 (Chr 2q14, P = 0.003), D19S903 (Chr 19p13, P = 0.003), and TNF-α (Chr 6p21, P < 0.001). Direct comparisons in pairs of the three groups by CLUMP T1-statistic were performed as detailed in Table 3 . Markers D4S432, D2S347, and D19S903 did not show any statistical differences between benign onset, aggressive, and primary progressive groups at the P < 0.0014 significance level.
The marker D3S1278 had significant differences between primary progressive and aggressive groups (P < 0.0001) but not between benign onset and aggressive groups (P = 0.11) or benign onset and primary progressive groups (P = 0.004). The CLUMP T3-statistic confirmed a difference between the primary progressive and aggressive groups in the 213 and 215 allele frequencies as shown in Figure 1A ; there is a shift toward allele frequency 215 in the primary progressive group.
The CLUMP T1-statistic showed that the TNF-α marker was significant between benign onset and aggressive groups (P < 0.0001) and benign onset and primary progressive groups (P < 0.0001) but not aggressive and primary progressive groups (P = 0.002). The CLUMP T3-statistic confirmed these differences as shown in Figure 1B with a difference between benign onset and aggressive groups in allele frequencies 249 and 251 and also 267 and 269. In the benign onset vs. primary progressive group, a difference was apparent for allele frequencies 249 and 251, with a shift toward 251 in the benign onset group. 
Discussion
We have demonstrated that five microsatellite markers known to influence susceptibility to MS in the Northern Irish population may also have a role on disease outcome: D3S1278 (Chr 3q13, P < 0.001), D4S432 (Chr 4p16, P = 0.001), D2S347 (Chr 2q14, P = 0.003), D19S903 (Chr 19p13, P = 0.003), and TNF-α (Chr 6p21, P < 0.001). Although markers D4S432, D2S347, and D19S903 were significant only in our preliminary analysis, further analysis using CLUMP was unable to identify where the differences lay. These markers might usefully be assessed in a larger replication study in a different population. Marker D3S1278 was significant for comparison between aggressive and primary progressive disease; however, clinically this would be of limited value. TNF-α has been shown to be significant for comparison of benign onset with both aggressive and primary progressive disease. The authors would acknowledge that this study was not ideally powered. The studies in TNF region of chromosome 6 are of particular interest because TNF-α and TNF-β are tandemly located within the HLA complex, suggesting that these genes may be in linkage disequilibrium with the HLA-DR loci that are associated with MS. TNF-α, in particular, has been repeatedly shown to confer susceptibility to MS in both linkage and association studies. Interestingly, in this study, the allele frequencies of the TNF-α marker proved to be significant between benign onset and aggressive groups (P < 0.0001) and benign onset and primary progressive groups (P < 0.0001). This would suggest that this marker may be the single most valuable predictor of disease outcome in MS in Northern Ireland population. This is in contrast with all previous studies which failed to demonstrate any association between TNF-α and disease course and severity [10] [11] [12] [13] [14] .
Clinically, the most valuable test would be able to predict between benign and aggressive MS. A statistically significant difference between the benign onset and aggressive cohorts was identified with TNF-α (P < 0.0001). This would support that this marker as a potential future test to discriminate between patients who will follow a benign or aggressive clinical course. An unbiased assessment of the value of this marker would be best obtained from a replication study.
In conclusion, this study supports the concept that DNA analysis for known microsatellite markers may help in predicting the disease outcome in MS in the clinical setting. TNF-α showed significant differences between benign onset and aggressive MS in the Northern Irish population indicating that it is the most valuable predictor of disease outcome in this population. This study also suggests a trend in disease outcome with markers D4S432, D2S347, and D19S903 which may warrant further study.
